The global gout disease treatment market, by Drug Class (Monoclonal Antibody, Colchicine, NSAIDs (Non-steroidal Anti-inflammatory Drugs), Corticosteroids, and Urate-lowering Agents), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), by Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and by Route of Administration (Injectable and Oral), had a market valuation of US$ 2,385.7 million in 2018, and is estimated to grow at a CAGR of 6.7 percent over the forecast period (2019-2027), as mentioned in a new report published by Coherent Market Insights.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/3082
Drivers
During the forecast period, the global gout disease treatment market is expected to grow due to an increase in the number of regulatory approvals for anti-gout medications. Gloperba, a colchicine oral solution 0.6 mg/5 ml, obtained FDA clearance in February 2019 from ROMEG Therapeutics. It is the first oral liquid colchicine solution to be approved by the FDA in the United States. The medication was created to help people avoid or handle gout attacks. AstraZeneca has obtained FDA clearance for ZURAMPIC (lesinurad) 200 mg tablets in December 2015. The medication is used to treat hyperuricemia associated with gout and combined with XOI (xanthine oxidase inhibitor).
The gout disease treatment market is projected to grow due to an increase in the acceptance of inorganic strategies such as partnership by key players in the pharmaceutical sector. In September 2019, Simcere Pharmaceutical Group and JW Pharmaceutical announced a partnership and exclusive license arrangement in China for the production of anti-gout drug candidate URC-102. Horizon Pharma plc and HemoShear Therapeutics, LLC have announced a partnership deal in January 2019 to produce novel gout therapeutics.
Furthermore, the gout disease treatment market is projected to expand at a faster rate over the forecast period due to an increase in the number of pipeline drugs. The University of Alabama at Birmingham, in conjunction with the University of Auckland in New Zealand, began a phase 2 clinical trial in February 2017 to investigate the safety and effectiveness of Denosumab, a fully human monoclonal antibody with a high affinity for RANKL, in combination with urate-lowering therapy (ULT) for the treatment of bone erosion associated with gout disease. By February 2020, the thesis should be finished. During the forecast period, these trends are likely to propel growth of the global gout disease treatment market.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/3082
Key Takeaways
Due to increased efforts by major players for the production of effective drugs for the treatment of gout, the global gout disease treatment market is expected to grow at a CAGR of 6.7 percent during the forecast period (2019–2027). Dyve Biosciences, Inc. will begin a phase 2 clinical trial in February 2020 to show the safety and effectiveness of DYV700 (drug candidate) for the treatment of acute gout flares following topical application.
Moreover, rising anti-gout drug approvals are projected to propel growth of the global gout disease treatment market during the forecast period. Hikma Pharmaceuticals obtained FDA clearance to commercialize Mitigare, a colchicine tablet, to avoid gout attacks in September 2014.
Key companies contributing in the global gout disease treatment market are JW Pharmaceutical Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, AstraZeneca Plc, Zyla Life Sciences (Pty) Ltd., CymaBay Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Simcere Pharmaceutical, Hikma Pharmaceuticals Plc, Teijin Pharma Limited, and Horizon Therapeutics Plc.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/3082
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Mergers and Acquisitions
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Epidemiology
- Market Dynamics
- Global Gout Disease Treatment Market, By Drug Class, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Colchicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million) Corticosteroids
- Urate-lowering Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Monoclonal Antibody
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Gout Disease Treatment Market, By Route of Administration, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Gout Disease Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Gout Disease Treatment Market, By Region, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teijin Pharma Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Simcere Pharmaceutical
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- JW Pharmaceutical Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Horizon Therapeutics plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hikma Pharmaceuticals Plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Ironwood Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zyla Life Sciences.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- CymaBay Therapeutics, Inc..
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AstraZeneca Plc
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837